In a new osteoarthritis (OA) genome-wide meta-analysis that used data from the UK Biobank and the Arthritis Research UK Osteoarthritis Genetics (arcOGEN) consortium, which included ~17.5 million single-nucleotide variants in >450,000 individuals of European descent, 64 genome-wide-significant regions have been identified. This study adds 52 new loci to the list of 34 already-known disease-associated loci in OA, including 24 for OA at any site, 15 for hip OA, 7 for knee OA and 6 for hip and/or knee OA. Ten of the putative effector genes are targets of approved therapeutics or therapeutics in clinical trials.